Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective

What this Trial Is About

Researchers are investigating how changes in angiopoietin levels may relate to complications after cardiac surgery involving cardiopulmonary bypass. This study focuses on the balance between angiopoietin 1 and angiopoietin 2, which can indicate damage to the lining of blood vessels and inflammation that may lead to organ failure. The goal is to understand how these changes might predict serious heart and lung problems following surgery. Participants will undergo scheduled cardiac surgery with cardiopulmonary bypass. During the surgery, 5 ml blood samples will be collected at the beginning and end of the procedure to measure angiopoietin levels. The study monitors participants for 28 days to assess major cardiovascular events and pulmonary complications, with follow-up to evaluate mortality rates up to 12 months. Throughout the study, researchers will analyze blood samples and track health outcomes including heart and lung complications, as well as survival at 3, 6, and 12 months after surgery. The primary focus is on the relationship between abnormal angiopoietin concentrations and adverse events within 28 days. Participants will be closely observed to gather these data, contributing valuable information about risks associated with cardiac surgery.

Angiopoietin and Adverse Outcomes in Cardiac Surgery